,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,64372,7,2,,103269645,5666,Active,,,0.155,Kd,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,Confirmatory,9871604.0,
1,109909,3,3,,103269645,5666,Unspecified,,,,,Amphetamine antagonistic activity on peroral administration in mice; value ranges from (13.2-22.4),Other,3806599.0,
2,109911,3,3,,103269645,5666,Unspecified,,,,,Antidepressant activity was assessed from the ability to antagonize reserpine-induced hypothermia on peroral administration in mice; value ranges from(3.1-7.),Other,3806599.0,
3,109918,3,3,,103269645,5666,Unspecified,,,,,Antidepressant activity was assessed from the ability to antagonize reserpine-induced palpebral ptosis on peroral administration in mice; value ranges from (0.7-3.3.),Other,3806599.0,
4,110033,3,3,,103269645,5666,Unspecified,,,,,Pentylenetetrazole antagonistic activity on peroral administration in mice; value ranges from(6.4-20.7).,Other,3806599.0,
5,127865,5,2,,103269645,5666,Unspecified,,,,,Evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported; 30-70% reduction,Other,6716399.0,
6,130125,6,2,,103269645,5666,Unspecified,,,,,Compound was evaluated for maximal electroshock antagonism (MES) against mice,Other,6716399.0,
7,132000,5,2,,103269645,5666,Unspecified,,,,,Evaluated for antagonism of reserpine induced hypothermia; 0.5-2.5 mg/kg,Other,6716399.0,
8,134420,6,2,,103269645,5666,Unspecified,,,,,"Lethal dose in mouse, in groups of ten",Other,6716399.0,
9,134948,3,3,,103269645,5666,Unspecified,,,,,Mouse behavior activity was determined; S-D=Stimulant-Depressant,Other,6716399.0,
10,144700,8,4,,103269645,5666,Inconclusive,,,,,"Noncompetitive inhibition of N-methyl-D-aspartate (NMDA) Receptor, by the displacement of [3H]MK-801 in rat brain membranes; nd means not determined",Other,9871604.0,
11,145563,7,2,,103269645,5666,Active,,,0.155,Kd,Equilibrium dissociation constant (KD) for Competitive binding between [3H]- nisoxatine and the compound at human Norepinephrine transporter,Confirmatory,9871604.0,
12,159537,6,3,,103269645,5666,Active,,,20.0,IC50,Tested for in vitro reuptake inhibition of [3H]-5-hydroxy tryptamine in pig frontal synaptosomes.,Confirmatory,3806599.0,
13,159538,6,3,,103269645,5666,Active,,,38.0,IC50,Tested for in vitro reuptake inhibition of [3H]dopamine in pig striatal synaptosomes.,Confirmatory,3806599.0,
14,159539,6,3,,103269645,5666,Active,,,0.22,IC50,Tested for in vitro reuptake inhibition of [3H]norepinephrine in pig occipital synaptosomes.,Confirmatory,3806599.0,
15,186979,7,3,,103269645,5666,Active,,,48.0,Ki,Inhibition of [3H]- DA reuptake into rat striatal synaptosomes,Confirmatory,9871604.0,
16,186980,7,2,,103269645,5666,Active,,,0.17,Ki,Inhibition of [3H]- NE reuptake into rat hippocampal synaptosomes,Confirmatory,9871604.0,
17,186981,7,3,,103269645,5666,Active,,,16.5,Ki,Inhibition of [3H]5-HT reuptake into rat frontal cortex synaptosomes,Confirmatory,9871604.0,
18,204080,7,3,,103269645,5666,Active,,,17.3,Kd,Equilibrium dissociation constant (KD) for Competitive binding between [3H]- imipramine and the compound at human transporter-hSERT,Confirmatory,9871604.0,
19,212885,3,3,,103269645,5666,Unspecified,,,,,Compound dose that causes lethality (acute toxicity) was determined by administering perorally in mice.,Other,3806599.0,
20,476929,3,3,,103269645,5666,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
21,540209,4,3,,103269645,5666,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
22,540210,4,3,,103269645,5666,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
23,540212,4,3,,103269645,5666,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
24,540213,4,3,,103269645,5666,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
25,1079931,1,1,,103269645,5666,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
26,1079932,1,1,,103269645,5666,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
27,1079933,1,1,,103269645,5666,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
28,1079934,1,1,,103269645,5666,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
29,1079935,1,1,,103269645,5666,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
30,1079936,1,1,,103269645,5666,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
31,1079937,1,1,,103269645,5666,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
32,1079938,1,1,,103269645,5666,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
33,1079939,1,1,,103269645,5666,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
34,1079940,1,1,,103269645,5666,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
35,1079941,1,1,,103269645,5666,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
36,1079942,1,1,,103269645,5666,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
37,1079943,1,1,,103269645,5666,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
38,1079944,1,1,,103269645,5666,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
39,1079945,1,1,,103269645,5666,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
40,1079946,1,1,,103269645,5666,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
41,1079947,1,1,,103269645,5666,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
42,1079948,1,1,,103269645,5666,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
43,1079949,1,1,,103269645,5666,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
44,1151051,1,1,,103269645,5666,Unspecified,,,,,Antidepressant activity in po dosed mouse assessed as antagonism of reserpine-induced hypothermia dosed 17 hrs after reserpine challenge,Other,966254.0,
45,1151052,1,1,,103269645,5666,Unspecified,,,,,Sedative activity in po dosed mouse assessed as reduction in locomotor activity during 60 mins period immediately prior to and after dosing,Other,966254.0,
46,1259407,1,1,,363907127,5666,Inactive,,,,,CCRIS mutagenicity studies,Other,,
47,1259416,1,2,,340080748,5666,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
48,1259421,1,1,,340080748,5666,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
